Zyla Life Sciences Quick Ratio (EGLT) starting from the first quarter 2020 to first quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Zyla Life Sciences  (EGLT)

Zyla Life Sciences's Quick Ratio

EGLT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2020, Quick Ratio fell to 0.16 below Zyla Life Sciences average.

Within Major Pharmaceutical Preparations industry 464 other companies have achieved higher Quick Ratio than Zyla Life Sciences in first quarter 2020. While Quick Ratio total ranking in the first quarter 2020 has deteriorated compared to the prior quarter from 3563 to 3988.

Explain Quick Ratio?
How much Cash & cash equivalents EGLT´s has?
What are EGLT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EGLT Quick Ratio (Mar 31 2020)
Q1		 (Dec 31 2019)
Q4		 (Sep 30 2019)
Q3		 (Jun 30 2019)
Q2		 (Mar 31 2019)
Q1
Y / Y Current Liabilities Change 125.1 % 128.6 % -53.34 % 4.21 % -0.12 %
Y / Y Cash & cash equivalent Change -60.47 % -70.32 % -62.97 % -82.78 % -50.6 %
Quick Ratio MRQ 0.16 0.16 0.24 0.19 0.89
EGLT's Total Ranking # 3988 # 3563 # 2506 # 2843 # 4095
Seq. Current Liabilities Change 22.79 % -0.43 % 17.92 % 56.13 % 24.71 %
Seq. Cash & cash equivalent Change 21.53 % -35.65 % 54.26 % -67.23 % -8.75 %



Quick Ratio first quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 465
Healthcare Sector # 857
Overall Market # 3988


Quick Ratio Statistics
High Average Low
28.8 4.51 0.14
(Mar 31 2014)   (Mar 31 2019)




Financial Statements
Zyla Life Sciences's Current Liabilities $ 93 Millions Visit EGLT's Balance sheet
Zyla Life Sciences's Cash & cash equivalent $ 15 Millions Visit EGLT's Balance sheet
Source of EGLT's Sales Visit EGLT's Sales by Geography


Cumulative Zyla Life Sciences's Quick Ratio

EGLT's Quick Ratio for the trailling 12 Months

EGLT Quick Ratio

 (Mar 31 2020)
12 Months		 (Dec 31 2019)
12 Months		 (Sep 30 2019)
12 Months		 (Jun 30 2019)
12 Months		 (Mar 31 2019)
12 Months
Y / Y Current Liabilities TTM Growth 3.33 % -13.95 % -30.47 % 61.25 % 91.13 %
Y / Y Cash & cash equivalent TTM Growth -71.03 % -66.21 % -62.29 % -58.72 % -44.43 %
Quick Ratio TTM 0.18 0.31 0.5 0.46 0.66
Total Ranking TTM # 5051 # 5069 # 2086 # 5022 # 4984
Seq. Current Liabilities TTM Growth 20.06 % 19.82 % -28.79 % 0.87 % -0.02 %
Seq. Cash & cash equivalent TTM Growth -28.02 % -26.31 % -22.69 % -29.37 % -16.03 %

Quick ratio ranking by company, industry and sector >> Back to EGLT Financial Strength Comparisons >> Go to Compare EGLT Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q1 2020 to $93.04 millions, cumulative Quick Ratio decreased to 0.18 below the Zyla Life Sciences average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 507 other companies have achieved higher Quick Ratio than Zyla Life Sciences. While Quick Ratio overall ranking has improved so far to 5051, from total ranking during the twelve months ending fourth quarter 2019 at 5069.

Explain Quick Ratio?
How much Cash & cash equivalents EGLT´s has?
What are EGLT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 508
Healthcare Sector # 978
Within the Market # 5051


trailing twelve months Quick Ratio Statistics
High Average Low
5.33 2.64 0.18
(Mar 31 2015)   (Dec 31 2019)




Companies with similar Quick Ratio in the quarter ending Mar 31 2020, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2020 MRQ Cash & cash equivalentMar 31 2020 MRQ Current Liabilities
Amneal Pharmaceuticals Inc   0.42 $ 406.925  Millions$ 965.065  Millions
Grace Therapeutics Inc  0.42 $ 4.869  Millions$ 11.566  Millions
Perrigo Company Plc  0.41 $ 510.400  Millions$ 1,254.600  Millions
Morphosys Ag  0.40 $ 122.970  Millions$ 305.965  Millions
Bausch Health Companies Inc   0.39 $ 912.000  Millions$ 2,341.000  Millions
Vaccinex Inc   0.38 $ 2.491  Millions$ 6.620  Millions
Allergan plc  0.35 $ 2,618.300  Millions$ 7,433.400  Millions
Abbott Laboratories  0.34 $ 3,668.000  Millions$ 10,808.000  Millions
Immunoprecise Antibodies Ltd   0.34 $ 1.934  Millions$ 5.701  Millions
Avalo Therapeutics Inc   0.33 $ 5.724  Millions$ 17.330  Millions
Gridai Technologies Corp  0.32 $ 1.671  Millions$ 5.143  Millions
Merck and Co Inc   0.32 $ 7,432.000  Millions$ 23,483.000  Millions
Elite Pharmaceuticals Inc   0.32 $ 1.207  Millions$ 3.826  Millions
Pfizer Inc  0.31 $ 10,350.000  Millions$ 33,890.000  Millions
Avricore Health Inc   0.26 $ 0.237  Millions$ 0.905  Millions
Ani Pharmaceuticals Inc  0.26 $ 20.414  Millions$ 79.356  Millions
Nrx Pharmaceuticals Inc   0.26 $ 0.081  Millions$ 0.316  Millions
Vtv Therapeutics Inc   0.24 $ 2.906  Millions$ 11.970  Millions
Eli Lilly And Company  0.22 $ 1,777.400  Millions$ 7,906.300  Millions
Health right Discoveries Inc   0.22 $ 2.067  Millions$ 9.362  Millions
Medicure Inc   0.22 $ 2.080  Millions$ 9.430  Millions
Reshape Lifesciences Inc  0.21 $ 2.117  Millions$ 10.295  Millions
Q Biomed inc   0.18 $ 0.741  Millions$ 4.109  Millions
Cytodyn inc   0.18 $ 7.057  Millions$ 39.955  Millions
9 Meters Biopharma Inc   0.17 $ 2.743  Millions$ 15.836  Millions
International Stem Cell Corporation  0.17 $ 0.708  Millions$ 4.205  Millions
Timber Pharmaceuticals Inc   0.17 $ 0.300  Millions$ 1.816  Millions
American Bio Medica Corporation  0.16 $ 0.581  Millions$ 3.648  Millions
Zyla Life Sciences  0.16 $ 14.541  Millions$ 93.041  Millions
The Greater Cannabis Company Inc   0.15 $ 0.295  Millions$ 1.909  Millions

Date modified: 2026-09-08T15:09:57+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.